Diadexus, Inc. and Mayo Clinic signed an agreement to collaborate in the areas of education, research, and innovation on the PLAC(r) Test for Lp-PLA2 Activity. The test, which has been cleared by the U.S. Food and Drug Administration, is used to help identify risk for coronary heart disease in patients with no history of cardiovascular events. As part of the agreement, Mayo Clinic's Department of Laboratory Medicine and Pathology will participate in the Diadexus Laboratory Partnership Program, where Diadexus will provide educational support during the proper integration and use of Lp-PLA2 Activity testing in the clinical practice.

Once fully integrated, the test will be available to patients and providers worldwide through Mayo Clinic's reference laboratory Mayo Medical Laboratories, which offers advanced laboratory testing and pathology services to more than 5,000 health care organizations.